Cargando…
An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese
Levofloxacin-induced severe cutaneous adverse drug reactions (LEV-SCARs) remain unexplored. An association study of human leukocyte antigen (HLA) alleles with LEV-SCARs among 12 patients, 806 healthy subjects, and 100 levofloxacin-tolerant individuals was performed. The carrier frequencies of HLA-B∗...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404721/ https://www.ncbi.nlm.nih.gov/pubmed/37554438 http://dx.doi.org/10.1016/j.isci.2023.107391 |
_version_ | 1785085360439558144 |
---|---|
author | Jiang, Menglin Yang, Jin Yang, Linlin Wang, Lina Wang, Ting Han, Shengna Cheng, Ye Chen, Zihua Su, Yu Zhang, Lirong Yang, Fanping Chen, Sheng-an Zhang, Jin Xiong, Hao Wang, Lanting Zhang, Zhen Ma, Li Luo, Xiaoqun Xing, Qinghe |
author_facet | Jiang, Menglin Yang, Jin Yang, Linlin Wang, Lina Wang, Ting Han, Shengna Cheng, Ye Chen, Zihua Su, Yu Zhang, Lirong Yang, Fanping Chen, Sheng-an Zhang, Jin Xiong, Hao Wang, Lanting Zhang, Zhen Ma, Li Luo, Xiaoqun Xing, Qinghe |
author_sort | Jiang, Menglin |
collection | PubMed |
description | Levofloxacin-induced severe cutaneous adverse drug reactions (LEV-SCARs) remain unexplored. An association study of human leukocyte antigen (HLA) alleles with LEV-SCARs among 12 patients, 806 healthy subjects, and 100 levofloxacin-tolerant individuals was performed. The carrier frequencies of HLA-B∗13:01 (odds ratio [OR]: 4.50; 95% confidence interval [CI]: 1.15–17.65; p = 0.043), HLA-B∗13:02 (OR: 6.14; 95% CI: 1.73–21.76; p = 0.0072), and serotype B13 (OR: 17.73; 95% CI: 3.61–86.95; p = 4.85 × 10(−5)) in patients with LEV-SCARs were significantly higher than those of levofloxacin-tolerant individuals. Molecular docking analysis suggested that levofloxacin formed more stable binding models with HLA-B∗13:01 and HLA-B∗13:02 than with non-risk HLA-B∗46:01. Mass spectrometry revealed that nonapeptides bound to HLA-B∗13:02 shifted at several positions after exposure to levofloxacin. Prospective screening for serotype B13 (sensitivity: 83%, specificity: 78%) and alternative drug treatment for carriers may significantly decrease the incidence of LEV-SCARs. |
format | Online Article Text |
id | pubmed-10404721 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-104047212023-08-08 An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese Jiang, Menglin Yang, Jin Yang, Linlin Wang, Lina Wang, Ting Han, Shengna Cheng, Ye Chen, Zihua Su, Yu Zhang, Lirong Yang, Fanping Chen, Sheng-an Zhang, Jin Xiong, Hao Wang, Lanting Zhang, Zhen Ma, Li Luo, Xiaoqun Xing, Qinghe iScience Article Levofloxacin-induced severe cutaneous adverse drug reactions (LEV-SCARs) remain unexplored. An association study of human leukocyte antigen (HLA) alleles with LEV-SCARs among 12 patients, 806 healthy subjects, and 100 levofloxacin-tolerant individuals was performed. The carrier frequencies of HLA-B∗13:01 (odds ratio [OR]: 4.50; 95% confidence interval [CI]: 1.15–17.65; p = 0.043), HLA-B∗13:02 (OR: 6.14; 95% CI: 1.73–21.76; p = 0.0072), and serotype B13 (OR: 17.73; 95% CI: 3.61–86.95; p = 4.85 × 10(−5)) in patients with LEV-SCARs were significantly higher than those of levofloxacin-tolerant individuals. Molecular docking analysis suggested that levofloxacin formed more stable binding models with HLA-B∗13:01 and HLA-B∗13:02 than with non-risk HLA-B∗46:01. Mass spectrometry revealed that nonapeptides bound to HLA-B∗13:02 shifted at several positions after exposure to levofloxacin. Prospective screening for serotype B13 (sensitivity: 83%, specificity: 78%) and alternative drug treatment for carriers may significantly decrease the incidence of LEV-SCARs. Elsevier 2023-07-13 /pmc/articles/PMC10404721/ /pubmed/37554438 http://dx.doi.org/10.1016/j.isci.2023.107391 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Jiang, Menglin Yang, Jin Yang, Linlin Wang, Lina Wang, Ting Han, Shengna Cheng, Ye Chen, Zihua Su, Yu Zhang, Lirong Yang, Fanping Chen, Sheng-an Zhang, Jin Xiong, Hao Wang, Lanting Zhang, Zhen Ma, Li Luo, Xiaoqun Xing, Qinghe An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese |
title | An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese |
title_full | An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese |
title_fullStr | An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese |
title_full_unstemmed | An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese |
title_short | An association study of HLA with levofloxacin-induced severe cutaneous adverse drug reactions in Han Chinese |
title_sort | association study of hla with levofloxacin-induced severe cutaneous adverse drug reactions in han chinese |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404721/ https://www.ncbi.nlm.nih.gov/pubmed/37554438 http://dx.doi.org/10.1016/j.isci.2023.107391 |
work_keys_str_mv | AT jiangmenglin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT yangjin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT yanglinlin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT wanglina anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT wangting anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT hanshengna anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT chengye anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT chenzihua anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT suyu anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT zhanglirong anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT yangfanping anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT chenshengan anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT zhangjin anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT xionghao anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT wanglanting anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT zhangzhen anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT mali anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT luoxiaoqun anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT xingqinghe anassociationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT jiangmenglin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT yangjin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT yanglinlin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT wanglina associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT wangting associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT hanshengna associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT chengye associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT chenzihua associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT suyu associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT zhanglirong associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT yangfanping associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT chenshengan associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT zhangjin associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT xionghao associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT wanglanting associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT zhangzhen associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT mali associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT luoxiaoqun associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese AT xingqinghe associationstudyofhlawithlevofloxacininducedseverecutaneousadversedrugreactionsinhanchinese |